FOR UK MEDIA ONLY
Global dermatology specialist company declares its commitment to share clinical trials data
From January 1, 2014, researchers, patient associations and healthcare professionals can gain access to LEO Pharma’s clinical trials data, the company announced today. LEO Pharma, a global dermatology specialist company headquartered in Denmark, declared its support for the increased global calls for transparency coming from many quarters, including patient groups, researchers and think tanks.
“Transparency in relation to clinical trials data is a scientific and ethical responsibility that facilitates informed healthcare decisions. As such it is core to the values of LEO Pharma and we are pleased to pledge our support”, announced Geraldine Murphy, Managing Director of LEO Pharma UK & Ireland.
LEO Pharma will share clinical trials data with interested researchers, healthcare professionals and patients in a way that will not reveal identifiable personal data.
Dr Sathish Kolli, Medical Director of UK & Ireland at LEO Pharma added “As a company our mission is to help people achieve healthy skin. We support the sharing of clinical trials data with researchers, patient groups and healthcare professionals as we believe it is crucial to the advancement of collective scientific understanding of dermatological and other diseases.”
Starting in January 2014, the company will gradually post summary results of clinical trials sponsored by LEO Pharma dating back to 1990 on the company’s corporate website. In addition, clinical study reports dating back to 1990 will be gradually published, starting with the most recent and with all available within the next three years.
Finally, LEO Pharma will evaluate each request from researchers, healthcare professionals and patient associations to receive access to anonymised patient-level data for approved products dating back to 2000. A Patient and Scientific Review board will be established to evaluate requests for patient-level data. The Board will comprise independent researchers and representatives from patient associations, and will meet four times annually to review requests for access to clinical trials data sponsored by LEO Pharma.
“LEO Pharma is a patient-centric company and for us that implies being transparent about the results from our clinical trials, so that we can enable patients and healthcare professionals to make informed decisions about treatment. We recognise the public health benefits associated with making clinical trials results available”, said Gitte P. Aabo, President and CEO of LEO Pharma.
For more information on LEO Pharma’s commitment to transparency, please see LEO Pharma’s Position on Public Access to Clinical Trials Information on www.leo-pharma.com.
- ENDS -
About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions.
Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions.
LEO Pharma is headquartered in Denmark and employs around 4,800 people worldwide.
For more information, visit www.leo-pharma.com
FTI Consulting: Chris Hall
Email: Chris.Hall@fticonsulting.com Tel: 020 3077 0499 or 07850709220
LEO Pharma UK/Ireland: Julie Wong, Head of Communications
Email: email@example.com Tel: 01844 276270 or 07825918989